Analyst rates MannKind a Hold: Q3 revenue rose 24% to $101.87 million, while repeat demand is unproven and dilution may come before positive cash flow.
MannKind's ReadyFlow could widen Furoscix's reach into more outpatient settings. Click here to read why I rate MNKD stock a speculative Buy.
Motley Fool Press Release.
Analysts initiate coverage: RSI Equal-Weight ($22), NWCL Neutral, HDRN Buy.
Detailed price information for Mannkind Corp (MNKD-Q) from The Globe and Mail including charting and trades.
MannKind (NASDAQ:MNKD) CFO Chris Prentiss outlined the company’s commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase
On September 9, MannKind Corporation (NASDAQ:MNKD) announced a licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere, an inhaled, rapid-acting glucagon-like peptide-1 receptor agonist aimed at weight management. The deal hands MannKind an equity stake in Rose Pharma, a board seat, and royalty rights on future sales, without saddling it with the […]
MannKind and Rose Pharma are partnering to develop an inhaled weight-loss treatment using the Technosphere dry-powder inhalation technology.
Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technologyMannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, pat
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that members of the MannKind management team will present at the following upcoming investor conferences: Cantor Global Healthcare Conference (New York, NY)Fireside Chat, Thursday, September 10, 2026, at 11:30 a.m. ET H.C. Wainwright 28th Annual Global Investment Conference (New York, NY)Fireside Chat, Tuesday, September 15, 2026, at 9:30 a.m. ET Links to the live
MannKind (MNKD) continues to draw attention after recent share price moves, with the stock closing at US$3.95. Investors are weighing its current market value of about US$1.31b against its latest financial profile. Over the past year, MannKind’s share price return has been weak compared with its recent 30 day and 90 day share price returns of 2.60% and 4.77%, while the 1 year total shareholder return declined 13.94%. This suggests that recent momentum is still trying to repair longer term...
This is the newest page. Registered accounts read further back.